Neurocrine Biosciences Inc (NBIX)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 486,000 | 332,100 | 213,900 | 101,400 | 106,700 |
| Revenue | US$ in thousands | 2,355,100 | 1,883,200 | 1,411,600 | 1,107,700 | 994,700 |
| Pretax margin | 20.64% | 17.63% | 15.15% | 9.15% | 10.73% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $486,000K ÷ $2,355,100K
= 20.64%
Based on the provided data for Neurocrine Biosciences Inc's pretax margin over the years, we observe the following trend:
- In December 31, 2020, the pretax margin stood at 10.73%, indicating that for every $1 of revenue generated, the company retained $0.1073 before accounting for taxes and other expenses.
- By December 31, 2021, the pretax margin had declined to 9.15%, suggesting a decrease in profitability and efficiency in generating earnings before taxes.
- However, there was a notable turnaround in the company's performance as of December 31, 2022, with the pretax margin increasing significantly to 15.15%, showcasing improved operational efficiency and cost management.
- This positive momentum continued into December 31, 2023, with a further increase in the pretax margin to 17.63%, suggesting effective strategic management and potentially higher profitability for the business.
- By December 31, 2024, Neurocrine Biosciences Inc achieved its highest pretax margin of 20.64%, indicating a substantial improvement in profitability and overall financial performance over the years.
In summary, Neurocrine Biosciences Inc's pretax margin experienced fluctuations but showed an overall positive trend, with a notable increase in recent years, reflecting improved operational effectiveness and potentially stronger financial health.
Peer comparison
Dec 31, 2024